No Detail Found!

Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population

Author(s)
Zahid Sadek Chowdhury Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka,Dhaka,Bangladesh
Farah Shahjin Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka,Dhaka,Bangladesh
Farhana Akter Department of Pharmacy, University of Asia Pacific,Dhaka,Bangladesh
Maizbha Uddin Ahmed Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka,Dhaka,Bangladesh
Mohammad Safiqul Islam Department of Pharmacy, Noakhali Science and Technology University,Sonapur, Noakhali,Bangladesh
Muhammad Shahdaat Bin Sayeed Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka,Dhaka,Bangladesh
Reazul Islam Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka,Dhaka,Bangladesh
Abul Hasnat Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka,Dhaka,Bangladesh
Abstract
Warfarin, an oral anticoagulant is one of the most widely prescribed drugs in modern medicine. Large interindividuals variability due to age, gender, diet, concurrent drug interactions and variations in CYP2C9 and VKORC1 genes make the management of warfarin therapy challenging and yet no study has been conducted on the Bangladeshi population. The aim of the study was to identify the role of VKORC1 and CYP2C9 polymorphisms in Bangladeshi population in dose requirement of warfarin. We studied 87 heart valve replacement patients who were prescribed warfarin for minimum of 6 months with a target International normalized ratio of 2.0-3.5. Genotyping of VKORC1rs9923231 (-1639 G>A), CYP2C9*2 and CYP2C9*3 was performed by Polymerase Chain ReactionRestriction Fragment Length Polymorphism. The frequencies of GG, AG and AA genotypes of VKORC1rs9923231 in the studied population were 87.4%, 8%, and 4.6% respectively whereas the frequencies of the CYP2C9*1/3 and CYP2C9*3/3 were 4.6% and 3.4% respectively. The CYP2C9*2 was not found in the studied population. The results of this study indicate that comparatively higher daily maintenance doses of warfarin were required to achieve the target INR for patients carrying both GG genotype of VKORC1rs9923231 and wild type variant of CYP2C9*3 whereas minimum dose were required for patient having AA genotype of VKORC1rs9923231 and *3/*3 variant of CYP2C9.
Publication Details
Page(s) 341-346
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 30, Issue: 2, Year: 2017

Request the full text from PASTIC

Keywords
Polymorphism, Bangladeshi population., CYP2C9, VKORC1, warfarin dose adjustment
0

Citations

0

Downloads

74

Views